Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database |
| |
| Authors: | Qiaoyi Zhang Srini Rajagopalan Panagiotis Mavros Samuel S. Engel Michael J. Davies Donald Yin Larry Radican |
| |
| Affiliation: | 1.Global Health Outcomes,Merck Sharp & Dohme Corp.,Whitehouse Station,USA;2.Med Data Analytics Inc.,Williamsville,USA |
| |
| Abstract: | ![]()
Introduction Sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, and exenatide, an injectable glucagon-like peptide-1 receptor agonist, are incretin-based therapies for the treatment of type 2 diabetes. This study examined differences in baseline characteristics between patients with type 2 diabetes initiating sitagliptin vs. exenatide treatment in clinical practice settings in the US. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
